



**FOR IMMEDIATE RELEASE**

**Selexis SA Enters Into Cooperative Relationship Agreement with Henogen SA**  
*Henogen to Use Selexis Technology Platform for Mammalian Cell Line Development*

Geneva, Switzerland – April 11, 2006 – Selexis SA, a Swiss-based biotechnology company specializing in high yield and stable cell line development for therapeutic proteins announced today that it has entered into a non-exclusive cooperative relationship agreement with Henogen SA (“Henogen”). Under the agreement, Henogen will have access to the Selexis technology platform and expertise for cell population generation (cell pool) and cell line development.

Specifically, Henogen will have the right to use the Selexis engineered cell lines at their Belgium production facility to produce proteins and antibodies for product research, development and manufacturing.

“We are pleased with the Henogen/Selexis alliance,” said Igor Fisch, CEO of Selexis. “Cell lines engineered with the Selexis technology platform and expertise will help Henogen customers get proteins and antibodies from gene to clinical validation faster and more cost efficient.”

Selexis’ technology platform, which includes MARtech™, is a proprietary system that improves the speed, yield and stability of production cell lines used for therapeutic protein manufacturing. Based on proprietary human MAR (Matrix Attachment Region), the patented MARtech™ enables cell population generation in 4 weeks (after transfection) and stable cell line development in 10 weeks (after transfection to first round of cell cloning). Additionally, MARtech™ has been found to increase recombinant protein expression in mammalian cells in suspension and in serum-free more than 10 fold.

- more -

SELEXIS EUROPE  
18 chemin des Aulx  
1228 Plan-les-Ouates  
Switzerland

T +41 (0)22 308 93 60  
F +41 (0)22 308 93 61

SELEXIS USA  
655, Montgomery St. STE 540  
San Francisco, CA 94111  
USA

T +1 415 273 51 41  
F +1 415 837 32 04

"We are very excited to be utilizing Selexis' world class cell line development technology and expertise," said Dr. Alex Bollen, Henogen's CEO. "We believe Selexis' technology platform may improve our large scale production of monoclonal antibodies and therapeutic proteins. Additionally, our customers will benefit from Selexis' ability to quickly and efficiently identify high-producing clones that enhance production yields."

### **About Selexis**

Selexis is a privately held biotechnology company dedicated to the development of expert services and innovative technologies for comprehensive and rapid solutions for stable, high yield mammalian cell line development and protein manufacturing for therapeutic drugs. The Company's unique seven step process, which includes Selexis' fourth generation patented MARtech™, reduces traditional cell line development (DHFR) from 12 months to 3 months (after transfection to isolating cell clones) without any change in the scale-up process. For more information please visit <http://www.selexis.com>

### **About Henogen S.A.**

Henogen is a biotechnology company addressing biomanufacturing issues under the general umbrella "from gene to clinical product." The Company has extensive knowledge in performing and/or accompanying partners through R&D, process development, cGMP production and phase I to III clinical trials. Among the products previously developed and produced are recombinant proteins, gene therapy viral vectors, vaccines and monoclonal antibodies. For more information please visit <http://www.henogen.com>

## Selexis SA Enters Cooperative Agreement with Henogen SA

Page 3

*This news release contains forward-looking statements that involve a number of known and unknown risks and uncertainties. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. These statements are only predictions and actual events or results in future periods may differ materially from what is currently anticipated. In particular, we cannot assure you that we will be able to successfully develop or commercialize products based on our technology, particularly in light of the significant uncertainty inherent in developing drug delivery products, conducting clinical trials and obtaining regulatory approvals, that our technologies will prove to be safe and effective, that our joint ventures or our collaborations with other companies in the U.S. and abroad will successfully develop products or become profitable, that our business strategy will be successful or that we will be able to carry out our plans for 2007.*

*MARtech™ is a trademark of Selexis, SA.*

### **MEDIA CONTACT:**

Robert Meister  
602-953-1716  
[robert.meister@selexis.com](mailto:robert.meister@selexis.com)

### **MORE INFORMATION:**

EUROPE  
Igor Fisch, Ph.D.  
41 (0)22 308 93 60  
[igor.fisch@selexis.com](mailto:igor.fisch@selexis.com)

UNITED STATES  
Cori Gorman, Ph.D., M.B.A.,  
415-273-5141  
[cori.gorman@selexis.com](mailto:cori.gorman@selexis.com)

###